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Abstract
Amyotrophic lateral sclerosis is a neurodegenerative disorder that primarily affects the
motor system, but extramotor involvement is common. Progressive muscle weakness
and wasting, including bulbar and respiratory muscles, limit survival to 2–5 years after
disease onset in most patients. The diagnosis is made on clinical grounds and is based
on the presence of signs of upper and lower motor neuron loss in different body regions
in the absence of other pathologies that can explain the symptoms and signs of the
patient. Making an accurate diagnosis can be difficult in early disease stages. ALS is a
heterogeneous disorder with variability in age at onset, in phenotypic presentation, in
the extent of frontotemporal involvement and in the disease progression rate. There is
a high unmet medical need for objective markers that aid in early diagnosis and in
predicting disease outcome. In this chapter, the current knowledge about the diagnos‐
tic and prognostic value of 18F 2-fluoro-2-deoxy-D-glucose-PET in ALS is discussed. The
potential of other targets and PET tracers to visualize different aspects of ALS disease
pathology is described.
Keywords: amyotrophic lateral sclerosis, frontotemporal dementia, extramotor in‐
volvement, FDG PET, neuroinflammation, imaging biomarker
1. Introduction
Amyotrophic lateral  sclerosis (ALS) is  a relentlessly progressive disorder,  however,  with
considerable variability in phenotype, disease progression and aetiology. Reliable prognosti‐
cation regarding unusually fast  or slow progression is  difficult  in clinical  practice.  Since
diagnosis is often delayed until patients are already a year into their disease, pharmacologi‐
cal treatment with riluzole is often postponed as well. Numerous therapeutic clinical trials
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
using other drugs have failed to show any benefit. These problems highlight the high need for
reliable  biomarkers  in  ALS.  Ideally,  such  a  biomarker  should  be  easily  accessible  and
affordable, as well as very sensitive and specific for ALS [1]. It should also be of prognostic
value and should change with disease progression making it suitable for treatment monitor‐
ing [1]. Besides peripheral biomarkers in blood and cerebrospinal fluid, several neuroimag‐
ing biomarkers have been proposed, of which several nuclear or molecular imaging targets
seem to be very promising. Although radionuclide imaging is not commonly used in clinical
practice  for  ALS,  recent  studies  suggest  that  various  aspects  of  ALS  pathology  can  be
visualized and quantified.
1.1. ALS and FTD: two overlapping disorders
In ALS, the motor system is primarily affected [2]. Degeneration of upper motor neurons
(UMNs) in motor cortex and lower motor neurons (LMNs) in the brain stem and spinal cord
results in a progressive weakness and wasting of limb, bulbar and respiratory muscles, limiting
survival to 2–5 years after disease onset.
In frontotemporal dementia (FTD), the degenerative process starts in the frontal and/or
anterior temporal cortex [3]. Depending on the neuroanatomical regions affected, disease
presentations include behavioural variant FTD (with changes in behaviour with apathy, loss
of empathy, hyperorality, repetitive behaviours or disinhibition and executive dysfunction)
or language variants of FTD (such as primary non-fluent aphasia and semantic dementia). The
disease progressively affects other cognitive functions. Survival after disease onset ranges from
5 to 8 years.
ALS and FTD are considered to be extremes of a disease spectrum [4]. In about 10% of patients,
both diseases co-occur. In another 30–40%, there is some degree of overlap, with mild motor
involvement in patients with FTD, or mild cognitive/behavioural impairment in patients with
ALS. About 50% of patients have pure FTD or pure ALS.
The only approved therapy for ALS is riluzole, which extends survival by only a few months,
whereas for FTD no disease modifying therapies are available. The cornerstone of the man‐
agement of patients with FTD/ALS remains multidisciplinary care and supportive measures.
Ten percent of ALS patients and 40% of FTD patients have a positive family history. Mutations
in a heterogeneous set of genes have been identified to cause this familial form of FTD/ALS [5].
The inheritance pattern usually is autosomal dominant. Mutations in SOD1, TARDBP and FUS
cause ALS and sometimes ALS-FTD, and mutations in GRN and MAPT cause FTD, but rarely
also ALS. However, by far the most common cause for ALS, FTD/ALS and FTD is the recently
discovered mutation in C9ORF72 [6, 7]. It underlies 30–50% of familial ALS (and ALS-FTD)
and 20–25% of familial FTD [8].
At the neuropathological level, an overlap between ALS and FTD is present as well. Especially,
cytoplasmic accumulations of TDP-43, the protein encoded by the TARDBP gene, are central
to the overlap between ALS and FTD, as most patients with sporadic ALS and about half of
patients with sporadic FTD have such pathology (FTD/ALS-TDP-43) [9]. In addition, several
of the genetic forms of FTD/ALS have TDP-43 aggregates, including mutations in TARDBP,
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C9ORF72 and GRN. TDP-43 is an RNA-binding protein with important functions in gene
transcription, splicing, RNA transport and stress granule formation. Accumulations of FUS,
another RNA-binding protein, with many structural and functional similarities to TDP-43, is
also central to FTD/ALS as mutations in FUS cause ALS, rarely FTD, and FUS pathology is also
observed in about 5% of sporadic FTD patients.
It has thus become clear that ALS is a neurodegenerative disease that primarily affects the
motor system, but that a variable degree of extramotor involvement is present in most patients
[4].
For treating physicians and for family members, it is important to uncover cognitive problems
in ALS, but it is not always easy to perform extensive neuropsychological testing in patients
with motor impairments. An imaging biomarker that reliably recognizes and measures both
motor and extramotor involvement in ALS patients would be an important achievement for
the management of ALS patients and for ALS research.
1.2. Need for an upper motor neuron marker
The diagnosis of ALS requires the presence of both UMN and LMN signs. LMN signs are often
readily appreciated on clinical examination and electromyography (EMG) is a very sensitive
method to confirm this and even detect subclinical LMN involvement. On the contrary,
providing evidence of UMN involvement can be challenging. First, the clinical signs of UMN
involvement (hyperreflexia, spasticity, pseudobulbar features, Hoffman’s reflex and extensor
plantar response) exhibit both a low sensitivity and interrater reliability. Second, there are no
reliable tests to show that UMN involvement exists. This lack of a reliable method to detect
UMN involvement and track the progressive loss of UMNs is an important blind spot in the
ALS field.
Various markers of UMN involvement have been proposed so far. First, the appearance of the
motor cortex on magnetic resonance imaging (MRI) has been shown to be altered in ALS
patients. At the group level, the thickness of the motor cortex is decreased, especially on 7T
MRI [10]. However, at the individual patient level, a clear atrophy can only be demonstrated
in around 50% of ALS patients because of considerable overlap with healthy controls [11, 12].
Other parameters like T2 hypointensity and increased quantitative susceptibility mapping
(QSM) are present in a high proportion of ALS patients. It probably reflects gliosis due to
activated microglia, but still lacks convincing sensitivity and specificity [10, 13, 14]. Second,
the appearance of the corticospinal tract (CST) on MRI has also been proposed as a potential
UMN marker. T2 hyperintensity of the CST in the posterior limb of the internal capsule is
present in almost 50% of ALS patients, while it is absent in other studies [14, 15]. Since only
severe hyperintensity seems to be clearly related with ALS and this occurs only late in the
disease course, it is of no value in the (early) diagnosis of ALS [16]. Diffusion tensor imaging
(DTI) of the CST seemed to be very promising at first, but unfortunately also turned out to lack
sensitivity and specificity [16–18]. Third, the functional assessment of the motor cortex and
CST by means of transcranial magnetic stimulation (TMS), with motor evoked potentials
(MEP) being the most important parameter, has been investigated as a potential UMN
biomarker. Literature data are unfortunately discordant: while several studies reported a
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cortical hypoexcitability [19, 20], others found a clear hyperexcitablity [11, 21, 22]. Moreover,
several studies showed that TMS cannot discriminate ALS patients from controls [18, 23], so
better methods to detect UMN loss in ALS are needed.
1.3. Need for a (differential) diagnostic test
An early and certain diagnosis of ALS is of utmost importance for clinicians and patients. It
allows an early initiation of riluzole therapy (as yet the only proven disease-modifying therapy
for ALS), an accurate communication about the diagnosis and an early recruitment into clinical
trials. Especially, in these early stages of the disease, the disease process may be amenable to
therapy.
However, in daily clinical practice, the time between symptom onset and diagnosis (the
diagnostic delay) is long, estimated to be 12–14 months in tertiary ALS referral centres [24].
There are various reasons for this delay, including patients-specific and doctor-specific delays.
Aspecific presentations and phenotypic variability at onset contributes to the delay. Observa‐
tion of patients, with repeat clinical examinations and electrodiagnostic testing is a reliable
method to correctly identify ALS patients that present early with only mild and focal motor
symptoms, but this approach increases the diagnostic delay. Some cases pose a differential
diagnostic problem with certain ALS mimicking diseases, also adding significantly to the
diagnostic delay. Since most of these diseases lack abnormalities on CT or MRI imaging, they
can impossibly be excluded by conventional imaging. Only a tool that allows to make a positive
diagnosis of ALS early in the disease course could solve this problem.
1.4. Need for a prognostic marker
ALS is a heterogeneous disorder. Not only the genetic causes and the age at onset, but also the
disease progression is highly variable. The median survival after disease onset is only
33 months and most patients die 2–5 years after disease onset. However, numerous cases of
extremely long and extremely short survival have been reported, making up the extreme ends
of a wide prognostic spectrum [25]. Making a reliable prognostic estimation is pivotal for both
patients and their families and neurologists likewise, but still largely impossible these days. A
variety of prognostic factors has been identified, such as age of onset, site of onset, rate of
symptom progression, comorbid frontotemporal involvement and nutritional and respiratory
status [26–31]. Although they are clearly of value, they all reflect divergent clinical disease
parameters and do not directly reflect the underlying disease process. The first prognostic
models taking into account the different known prognostic factors are underway [32]. Other,
more pathophysiologically relevant biomarkers, such as pNFH levels [33, 34], seem to be
promising. But also imaging biomarkers that reliably reflect the extent of motor and extramotor
involvement have the potential to become a reliable prognostic determinant.
1.5. Need for an in vivo marker of ALS pathophysiology
Conventional neuroimaging has only revealed gross pathological insights by showing atrophy
of the motor cortex and alterations of the CST. These imaging modalities can reveal structural
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changes in ALS at the group level with high spatial resolution. However, they lack the capacity
to provide a reflection of the neuropathological process at the cellular or molecular level and
are not applicable at the individual patient level. Imaging biomarkers that can visualize ALS
disease pathology, such as neuroinflammation, neuronal death and ideally TDP-43 accumu‐
lation would greatly advance the field of ALS research. It would not only be valuable for
diagnostic purposes, but would also be useful to monitor the evolution of disease over time
and as a readout for treatment effects of disease-modifying therapies.
So far, positron emission tomography (PET) has not been commonly used in ALS. However,
recent studies show that various radioligands have potential to be useful imaging biomarkers
in ALS. These can be of value in the diagnosis, in predicting outcome and in imaging disease
pathology in ALS. In this chapter, an overview of the PET studies in ALS is given and future
perspectives on the use of PET in ALS are discussed. On overview of all tracers used in ALS
Figure 1. PET tracers used in ALS. Using PET imaging six different neurological systems or cell populations can be
assessed using different tracers. General glucose metabolism in the grey matter is assessed by [18F]-FDG. Cortical amy‐
loid deposition can be assessed using [11C]-PIB to distinguish ALS from Alzheimer’s disease. The extrapyramidal sys‐
tem can be investigated using [18F]-fluorodopa, [18F]-FPCIT or [123I]-FP-CIT. Neuronal integrity can be visualized using
tracers for the GABA-A receptor ([11C]-flumazenil) or the 5-HT1A receptor ([11C]-WAY100635). Microglial cells can be
highlighted using tracers targeting the translocator protein (TSPO), like [18F]-DPA-174, [11C]-(R)-PK11195 or [11C]-
PBR28. Astrocytes are visualized by tracers for the MAO-B enzyme ([11C]-DED).
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so far is provided in Figure 1. Apart from the commonly used tracers for indirect neuronal
functioning, such as glucose metabolism ([18F]-FDG) and perfusion, more specific receptor or
protein deposition tracers used in other neurodegenerative diseases, like Parkinson’s disease
([18F]-FP-CIT) and Alzheimer’s disease ([11C]-PIB), have also been investigated in ALS patients.
Recently, tracers with an affinity for specific cell types, like neurons ([11C]-flumazenil, [11C]-
WAY100635), microglial cells (TSPO ligands) and astrocytes ([11C]-DED), can also highlight
specific pathophysiological processes of ALS.
2. FDG PET imaging in ALS
2.1. Early FDG PET and perfusion SPECT studies revealed widespread cortical
abnormalities
In the 1980s and 1990s of the previous century a mere handful of studies investigated a small
number of ALS patients using 18F-2-fluoro-2-deoxy-D-glucose PET (FDG PET) imaging. The
common denominator of their findings was a generalized cerebral hypometabolism [35–37].
Despite the low spatial resolution of the PET scanners at the time, some studies did reveal a
predominance for the motor cortex [36] and even provided preliminary evidence for frontal
hypometabolism [37, 38] which was even related to clinical cognitive impairment in one study.
A few studies assessing cerebral perfusion using SPECT imaging confirmed a predominant
involvement of the motor cortex with extensive frontal hypoperfusion, often related to
cognitive impairment [39–41]. These pilot studies were instrumental in redirecting the view
of ALS as a disease exclusively affecting motor neurons towards a multisystem neurodege‐
nerative disease as generally accepted nowadays.
2.2. Regions involved on recent FDG PET imaging
More recent FDG PET studies in ALS patients, using the next-generation PET scanners with
higher spatial resolution, could confirm the presence of hypometabolism in the primary motor
cortex, which is hence thought to be the signature of ALS on FDG PET imaging [42–44]. Besides
the primary motor cortex, other peri-Rolandic regions like the premotor cortex and primary
sensory cortex have been found to be affected on FDG PET [42–45]. In keeping with the clinical
and pathophysiological overlap with FTD, several prefrontal (dorsolateral prefrontal cortex,
orbitofrontal cortex, anterior frontal cortex) and temporal (anterior temporal lobe, fusiform
gyrus) regions frequently display hypometabolism in ALS patients [42–45]. Some studies even
report hypometabolism of primary and associative visual cortices in ALS patients [42, 45].
Examples of typical FDG PET patterns seen in ALS are given in Figure 2. Patient 1 is an example
of an ALS patient with modest hypometabolism in the peri-Rolandic areas on FDG PET. In
patient 2, extensive hypometabolism in the motor cortex can be noted. In about 10% of patients,
extensive regions of hypometabolism are also present in the frontal and/or anterior temporal
lobes. Patient 3 is an example of an ALS patients with extensive areas of hypometabolism in
the frontal areas. Patient 4 has pronounced anterior temporal hypometabolism.
Update on Amyotrophic Lateral Sclerosis28
Figure 2. Commonly affected regions on FDG PET in ALS patients. Three regions frequently and typically display
hypometabolism on FDG PET in ALS patients; motor cortex, prefrontal cortex and anterior temporal lobe. The three
left images depict the stereotactic surface projections of brain FDG PET uptake. The three images on the right show the
corresponding Z-score images (comparing patient to healthy volunteers). In patient 1 and 2, hypometabolism in the
Rolandic area (including parts of the motor cortex) is noted. While this is only mild in patient 1, patient 2 has extensive
hypometabolism. In patient 3, an obvious hypometabolism in the prefrontal cortex is noted. In patient 4, extensive hy‐
pometabolism of the anterior temporal lobe is noted.
Recently, several studies also reported the presence of (relative) hypermetabolism on FDG PET
in certain regions. Hypermetabolism in ALS patients seems to be most obvious in the infra‐
tentorial region, like midbrain, pons and cerebellum [44–46]. This hypermetabolism is thought
to be the reflection of increased astrocytosis along the course of the CST [45]. Also, hyperme‐
tabolism in mesial temporal structures, like hippocampus and amygdala, has been reported
[44, 45].
2.3. Detection of frontotemporal involvement on FDG PET
As explained above, a clear link between ALS and FTD has been established over the last years.
This is also backed up by the early studies showing frontotemporal hypometabolism using
FDG PET and rCBF measures [37, 38]. Based on the extent of frontotemporal versus motor
neuron involvement, patients across the ALS-FTD spectrum can be divided into five categories
[47]. Pure ALS (without any evident cognitive abnormality) and pure FTD (without any
obvious motor abnormality) are located at the opposite ends of this spectrum. Patients who
meet diagnostic criteria for both ALS as FTD are considered to have ‘ALS-FTD’. ALS patients
with mild behavioural dysfunction are classified as having ALS with behavioural impairment
(‘ALSbi’), whereas patients with mild executive and language dysfunction are said to have
ALS with cognitive impairment (‘ALSci’). Patients with a diagnosis of FTD and some motor
neuron involvement are said to have ‘FTD-MND’.
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The signature of frontotemporal involvement on PET imaging constitutes hypometabolism
mainly focused on the prefrontal cortex, often extending to the entire frontal cortex and
anterior temporal cortex and even to the thalamus [48, 49]. Contrary to FTD patients, this
frontotemporal hypometabolism is often more symmetric in ALS-FTD patients [49]. Impor‐
tantly, this hypometabolism is often already present in otherwise normal frontotemporal lobes
on MRI, leading to the general view that hypometabolism precedes atrophy [50]. This makes
FDG PET a very sensitive tool to detect frontotemporal involvement even in a very early clinical
stage. Hence, frontotemporal hypometabolism on FDG PET has extensive potential to become
an important diagnostic marker, and this independently from hypometabolism in the primary
motor cortex.
Several studies performing both PET imaging as neuropsychological testing in ALS patients
found a correlation between extent of frontotemporal hypometabolism and neuropsycholog‐
ical performance [37, 38, 43]. A recent large study indeed confirmed that ALS patients with
mild cognitive impairment (‘ALSci’) exhibit moderate frontotemporal hypometabolism, which
is clearly more pronounced in real ‘ALS-FTD’ patients and less pronounced to even absent in
‘pure ALS’ patients [48]. So, when patients are stratified along the ALS-FTD spectrum, there
seems to be a proportionate correlation between clinical cognitive involvement and fronto‐
temporal hypometabolism on PET imaging.
Frontotemporal hypometabolism on PET not only has the potential to become a diagnostic
marker, it has also been shown to provide important prognostic information. In a considerably
large study of ALS patients, extensive prefrontal hypometabolism was associated with
significantly shorter survival [51].
2.4. FDG PET as a (differential) diagnostic marker
Extensive studies demonstrating high diagnostic accuracy are a prerequisite for any imaging
biomarker to become incorporated into the diagnostic criteria of ALS. Recently, four large
studies assessed the sensitivity and specificity of FDG PET in ALS patients compared to healthy
controls. The first study made use of a ‘region of interest method’ [42]. When all brain regions
were taken into account, FDG PET was able to discriminate ALS patients from controls with
a sensitivity of 89% and specificity of 82.5%. When only a specific set of regions was used, an
even higher sensitivity (95%) with the same specificity (82.5%) could be obtained. The second
study analysed FDG PET images using a method evaluating disease-specific spatial patterns
on a voxel-based manner, trying to disclose the networks with the highest diagnostic value
[52]. When all relevant networks were taken into account an astonishing accuracy of 99.0%
was achieved. Remarkably, when only the most discriminating network (i.e. bilateral cerebel‐
lum and midbrain) was used, accuracy was still 96.3%. The third study reported an accuracy
of 89.7% using a VOI-based discriminant analysis, further increasing to 95% if a discriminant
analysis based on a support vector machine (SVM) approach was used [44]. In the fourth study,
a prospective validation of the diagnostic algorithm based on SVM was carried out in 105 novel
cases and a sensitivity and specificity of 100% was obtained [51]. All these studies suggest that
FDG PET is a very sensitive marker of ALS pathology that can be used in a clinical setting.
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There is, however, one major limitation of these studies. While these studies report a high
sensitivity using healthy controls, it is clear specificity may be lower since ALS patients need
to be discriminated from patients with ALS mimicking diseases. Unfortunately, no large
studies using FDG PET in such disease mimics exist. A study performing FDG PET in ten
patients with Kennedy’s disease even surprisingly revealed the presence of frontal hypome‐
tabolism [53]. This means that FDG PET may be insufficient to discriminate ALS from certain
ALS mimicking diseases.
2.5. FDG PET as a prognostic marker
Besides its capacities as a diagnostic marker, FDG PET is increasingly proposed as a potential
marker for prognosis. So far, only two studies assessed the value of FDG PET in predicting the
prognosis of ALS [44]. Assessing 70 ALS patients, extensive prefrontal hypometabolism was
associated with a significantly shorter survival. This is in line with previous studies that
reported concomitant clinical FTD or cognitive/behavioural impairment with a worse prog‐
nosis [4]. More recently, a larger prospectively collected cohort of 175 (including the initial 70
patients) was studied [51]. It was confirmed with longer follow-up that extensive hypome‐
tabolism in the prefrontal or anterior temporal lobe was associated with a shorter survival. In
a Cox regression, taking into account other prognostic factors, such as age of onset, site of onset,
diagnostic delay, FVC and slope in the ALS FRS-R, extensive frontotemporal hypometabolism
was significantly correlated with shortened survival (Figure 3).
Figure 3. Relation of ALS survival with degree of frontotemporal hypometabolism. Kaplan-Meier survival plot of all
ALS patients (ALS group 1 + ALS group 2) with (red line, n = 34) and without (blue line, n = 141) extensive hypometab‐
olism in the frontal and/or temporal cortex (n = 175, p < 0.001) (This research was originally published in JNM. Van
Weehaege et al. prospective validation of 18F-FDG brain PET discriminant analysis methods in the diagnosis of amyo‐
trophic lateral sclerosis. J Nucl Med. 2016;vol:pp-pp. © by the Society of Nuclear Medicine and Molecular Imaging, Inc.)
[51].
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3. Other tracers
3.1. Tracers assessing the extrapyramidal system
The exact role of the extrapyramidal system in the pathophysiology of ALS is still under debate.
Although several large clinical studies reported the increased presence of extrapyramidal
symptoms and signs (increased tonus, postural instability and backward falls) in ALS patients
[54, 55], others even reported an increased incidence of Parkinson’s disease in the ALS
population [56]. The presence of extrapyramidal symptoms in ALS is correlated with the
presence of a hexanucleotide repeat expansion in C9orf72 in many patients [57, 58]. PET studies
have tried to make a significant contribution in elucidating a possible link between ALS and
extrapyramidal symptoms.
[18F]-fluorodopa was one of the first radioligands used to assess the integrity of the nigrostriatal
tract with PET by quantifying dopadecarboxylase activity presynaptically, while nowadays
dopamine transporter imaging due to its better access using [123I]-FP-CIT SPECT is the most
widely used method to assess the extrapyramidal system. More novel and specific tracers such
as [18F]-PE2I for PET dopamine transporters are already in use at several centres worldwide
[59].
Literature data regarding extrapyramidal radionuclide imaging in ALS patients is still
sporadic and seems to be discordant. While two earlier studies reported a dopaminergic deficit
in sporadic and familial ALS patients without clinical extrapyramidal disease [60, 61], this was
contradicted in a more recent small study investigating ALS patients with concomitant clinical
parkinsonism (‘ALS-parkinsonism’) [62]. Another study did report dopaminergic deficits in
two ALS-parkinsonism patients assessed by [18F]-FP-CIT PET [63]. These discrepancies are
believed to be due to the heterogeneity of ALS-parkinsonism, and larger datasets are needed.
While in some cases the extrapyramidal signs are thought to be caused by true degeneration
of the extrapyramidal system, in other cases, they are believed to be the result of cortical lesions.
The latter concept is confirmed by a more recent study investigating UMN-ALS patients using
[123I]-FP-CIT SPECT [64]. While a dopaminergic deficit was indeed evident in the majority of
patients which even correlated with disease duration, there was no correlation with functional
extrapyramidal scores (like UPDRS). This means that, although the neuropathological process
in ALS extends towards the extrapyramidal system, some of the extrapyramidal signs noted
in ALS patients are probably due to spasticity, which is a typical UMN feature.
3.2. Tracers for neuroinflammation
Neurons rely on several supportive cells, commonly named glial cells, to survive and exert
their normal function. These glial cells, including astrocytes, microglia and oligodendrocytes,
provide nutritional and trophic support to neurons, especially motor neurons. ALS is charac‐
terized by a neuroinflammatory reaction consisting of an activation of astrocytes and micro‐
glia. Several studies using ALS animal models have taught us that dysfunction of these cell
types significantly contributes to motor neuron death, independent of intrinsic motor neuron
dysfunction, leading to the view of ALS as a non-cell autonomous disease [65].
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Two targets have been used to visualize this ‘neuroinflammation’ in ALS patients using
radionuclide imaging. [11C]-DED, a deprenyl derivative, selectively binds the MAO-B enzyme
which is primarily though not exclusively located in astrocytes. Because of the high back‐
ground activity of this ligand and newer derivatives, they are limited to research applications.
The second, more frequently used target is the activated microglial cell, the macrophages of
the central nervous system [66]. One of the most studied targets for activated microglia is the
translocator protein (TSPO), a mitochondrial protein that is highly overexpressed in activated
microglia [67]. Several radioligands such as [11C]-(R)-PK11195, [18F]-DPA-174 and [11C]-PBR28
can be used to quantify TSPO binding.
The major finding in TSPO PET studies in ALS is an increased binding in the motor cortex,
highlighting this region as the primary focus of neuropathology [68–70]. The degree of
neuroinflammation in the motor cortex is positively correlated with clinical UMN scores and
probably negatively correlated with ALS-FRS. Other frequently involved regions are the
prefrontal cortex, thalamus, pons and CST [68–71]. The latter two probably reflect the secon‐
dary neuroinflammation due to degeneration of the CST. Interestingly, some studies have
shown that the inflammation can be detected on the individual patient level.
Thus, PET imaging assessing neuroinflammation has a high potential to become a specific
UMN marker which can be used at the single patient level. Moreover, it could be an interesting
method to monitor the effect of treatment selectively targeting the neuroinflammatory process.
3.3. Tracers reflecting neuronal loss and/or dysfunction
Although the neurodegenerative process in ALS is non-cell autonomous, markers of selective
motor neuron death would be of significant value. FDG PET assesses glucose metabolism in
general, hence encompassing various processes like neuronal dysfunction, atrophy, micro‐
gliosis and astrocytosis. Therefore, the capabilities of FDG PET to selectively assess motor
neuron degeneration are limited.
Two tracers have been used so far to specifically assess neuronal loss and/or dysfunction. [11C]-
flumazenil, which selectively binds GABA-A receptors expressed by neurons, is the most
widely used. It is, however, unclear whether this ligand primarily visualizes pyramidal
neurons (like motor neurons) or interneurons. Although an early study reported an almost
generalized decreased signal in the cortex [72], more recent studies revealed a more selected
involvement of primary motor and motor association cortices, which was even correlated with
a clinical UMN score [73, 74]. One study used the radioligand [11C]-WAY100635 targeting the
5-HT1A serotonin receptor which is expressed in pyramidal neurons [75]. They also reported
a generalized cortical decrease, which was most pronounced in the motor cortex and fronto‐
temporal regions.
So, these neuronal radioligands seem to be able to specifically highlight the primary patho‐
physiological process of ALS, which is degeneration and dysfunction of the UMNs. Hence, it
seems promising to further investigate the diagnostic and prognostic value of these potential
UMN markers.
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4. Correlation with phenotype
4.1. ALS subtypes
The pattern of motor neuron involvement in ALS is highly heterogeneous. Depending on the
relative upper and LMN involvement and depending on the neuroanatomical region within
the motor system with the most extensive pathology, different subtypes of motor neuron
degeneration have been defined. While in some patients UMN features (spasticity, hyperre‐
flexia) dominate the clinical picture, LMN features prevail in other patients. It remains unclear
if the pure UMN disorder, PLS (primary lateral sclerosis), and the pure LMN disorder,
progressive muscular atrophy (PMA), should be regarded as separate disease entities or
merely as the extreme ends of the ALS spectrum [25]. Similarly, the site of onset is also highly
variable, with onset in a limb (‘spinal onset’) being more frequent than onset in the bulbar
musculature (‘bulbar onset’) [25]. The neuroimaging signature of these subtypes has not yet
been extensively studied using PET. The challenge will be to find commonalities and differ‐
ential representations of the different endophenotypes.
4.1.1. PLS and Mills’ syndrome
PLS is a variant of ALS with selective UMN signs for several years [76]. Mills’ syndrome is an
unusual unilateral variant of PLS, which eventually spreads to the contralateral side after a
variable time period [25]. On postmortem examination, there is no difference in the essential
pathological processes (e.g. TDP-43 positive intraneuronal inclusions) [77]. However, to
explain this phenotypic variability, there must be a difference in the focal initiation and
spreading pattern of the neurodegeneration. PET imaging has several advantages to assess
this question, like in vivo usability and availability of specific tracers. Unfortunately, since no
large studies investigating PET in PLS/Mills’ patients have been undertaken so far, we need
to rely on a handful of small case series. Four studies in PLS patients performed either FDG
PET or [11C]-flumazenil PET and mainly found similar abnormalities as seen in ALS patients
[44, 51, 78, 79]. However, in one study involvement of the primary motor cortex seemed to be
more severe than in pure ALS [79]. On the other hand, some specific regions like the prefrontal
cortex and posterior cingulate seem to be spared in PLS [44, 78]. So, based on these PET
findings, neuropathology in PLS may be more restricted to the motor cortex.
Only five cases of Mills’ patients with PET imaging have been reported so far. While one patient
had an asymmetric involvement of the motor cortices, an almost unilateral pattern of hypo‐
metabolism (FDG PET) or hypercaptation (TSPO radioligand) has been noticed in the four
remaining patients [80–82]. So, compared to PLS, neuropathology in Mills’ syndrome seems
to be focused even more on one unilateral motor cortex, suggesting a more restricted contig‐
uous spread of disease in this endophenotype.
4.1.2. PMA
PMA is a motor neuron disease with selective involvement of the LMN, and probably has to
be seen as an unusual variant of ALS [25]. Literature regarding FDG PET in PMA patients is
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very limited. Only two early studies performing FDG PET in ALS patients performed a
subanalysis in patients with only LMN signs. In keeping with the clinical absence of UMN
signs, no to only very mild cerebral hypometabolism is present in these patients [35, 36]. Larger
studies are required to establish if peri-Rolandic hypometabolism is present in a proportion
of PMA patients and if this predicts progression to ALS or disease outcome.
In comparison, a few MRI-based imaging studies investigating UMN involvement in PMA
remained inconclusive as well. One study found no evidence for thinning of the motor cortex
on high-resolution MRI [83]. While one study found modest though clear abnormalities of the
CST on DTI imaging [84], this was contradicted by another earlier study [85]. Finally, an fMRI
study revealed modest prefrontal activation abnormalities in PMA patients [86].
So based on several imaging modalities, it is so far unclear whether significant measurable
UMN involvement is present in all PMA patients.
4.1.3. Spinal versus bulbar
In most ALS patients, the disease starts with asymmetric weakness of a limb, and hence, this
classical form of ALS is called ‘spinal onset ALS’. In about 20% of ALS patients, however,
weakness starts in the bulbar muscles, this form is called ‘bulbar onset ALS’ [25]. While both
endophenotypes clearly have a distinct disease initiation and disease course, they eventually
converge into a common phenotype of generalized weakness. The pathological substrates
underlying these initial differences are largely not understood. PET imaging has tried to
elucidate some aspects of this enigma.
While one study using FDG PET suggested a differential pattern of involvement between
spinal and bulbar onset ALS in frontal and parietal regions [45], this was not confirmed by
others [42]. A study investigating perfusion (regional cerebral blood flow, rCBF) in ALS
patients reported a significantly lower rCBF of the frontal lobe in bulbar onset patients
compared to spinal onset [87]. Based on TSPO PET imaging, one study found evidence for
increased neuroinflammation in the brainstem of bulbar onset ALS patients, whereas neuro‐
inflammation in the motor cortex seemed to be less pronounced [70]. So, the specific functional
imaging correlate of these two endophenotypes has not been clearly established yet.
4.2. Severity of disease
An independent objective marker for severity and spreading pattern of disease pathology is
highly needed. None of the imaging biomarkers so far has been able to reflect local disease
severity and disease spreading in a longitudinal fashion. A limited amount of studies inves‐
tigated the link between PET imaging and clinical scores. First, although several FDG PET
studies in ALS patients found no correlation with parameters of disease severity in general,
one study did reveal a correlation of prefrontal hypometabolism with a reduced ALS-FRS R
(ALS functional rating scale revised version) [44]. Second, PET imaging of microglia, via TSPO
radioligands, was not correlated with ALS-FRS R in two studies [68, 69]. However, one of these
studies found a relation with clinical burden of UMN signs [68]. Third, abnormalities on [11C]-
flumazenil PET in one study was not correlated with ALS-FRS, whereas it was associated with
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the UMN score [74]. So in general, findings with the currently available PET targets show very
little, if any, clear correlation with clinical severity of disease. Longitudinal studies are required
to find out if PET imaging is of value in tracking disease progression.
5. Correlation with genotype
While most cases of ALS are sporadic, about 10% are caused by a variety of genetic deficits,
with alterations in the C9orf72 and SOD1 gene being the most frequent and most studied [88].
A few PET studies have been performed in genetic subtypes of ALS.
5.1. C9orf72
Two recent studies investigated 26 patients in total with C9orf72-related ALS using FDG PET
and found in general more severe hypometabolism [44, 46]. Remarkably, both studies also
reported hypometabolism in the thalamus and parts of the limbic system to be present almost
uniquely in C9orf72 patients. An example of FDG PET findings in a C9orf72 ALS patient is
Figure 4. PET abnormalities in a C9orf72 ALS patient. Example of Z-score images of FDG PET imaging of a C9orf72
patient with ALS revealing a remarkable hypometabolism of the thalamus, as noted on axial (A and B) and sagittal (C
and D) sections.
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provided in Figure 4. This involvement of thalamus, extrapyramidal system and limbic system
is probably the neuroanatomical correlate of the increased incidence of phenocopies of several
other neurodegenerative diseases in C9orf72 mutation carriers. Among others, phenocopies of
Parkinson’s disease, Huntington’s disease, corticobasal degeneration, Alzheimer’s disease and
several neuropsychiatric diseases (psychosis, schizophrenia) have been reported in C9orf72
mutation carriers [57].
5.2. SOD1 (D90A)
Worldwide, the D90A is the most common SOD1 mutation, although it is not the most studied
one [89]. This mutation can be inherited in an autosomal recessive or dominant way, which is
quite unusual in ALS. Two studies performing [11C]-Flumazenil-PET in a total of 21 D90A
patients revealed that these patients showed a specific pattern of reduced tracer binding
confined to the left frontotemporal junction and anterior cingulate gyrus, without involvement
of the motor and premotor cortices [73, 74]. Larger studies on other SOD1 mutations or other
genetic subtypes of ALS are largely lacking.
6. Future perspectives
More than a decade PET imaging has seen a revival in the ALS field using either new hardware
and software technologies or novel tracers. In the near future, PET will hopefully find
applications in both clinical practices, namely clinical trials and neurobiological research.
First, PET imaging could become of value in the ALS diagnosis in the future. Although
conventional imaging (e.g. MRI) is only intended to rule out other diseases, FDG PET has the
potential to be used as a positive argument to make a diagnosis of ALS at the single patient
level. Both hypometabolism in the motor cortex as in the frontotemporal cortex will be of
diagnostic value and could be considered to incorporate in clinical criteria for ALS, similar to
the inclusion of frontotemporal hypometabolism in the diagnostic criteria of FTD [90].
However, additional research comparing ALS patients with ALS mimicking diseases is needed
to reliably assess the sensitivity and especially the specificity in the real-life clinical setting of
early diagnosis.
Second, PET imaging will be further investigated as a biomarker of disease. More studies
assessing the correlation with severity of disease need to be undertaken. Similarly, more
longitudinal studies are needed to relate early PET abnormalities with clinical course, hope‐
fully fulfilling the high need for a prognostic marker in the clinic.
Third, PET imaging could become valuable in clinical trials of ALS patients. By increasing the
diagnostic yield, especially early in the disease, it will be possible to include patients early after
disease onset, hence increasing the power to obtain positive results in pharmaceutical trials.
Additionally, several tracers (neuroinflammation, neuronal loss …) could be used as a read
out to demonstrate target engagement or even to assess the effect of treatments. Of particular
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interest, a tracer for TDP-43 would revolutionize the field, as PET detection and quantification
of misfolded proteins have done in Alzheimer’s disease with beta-amyloid and tau imaging.
Fourth, tracers assessing neuroinflammation will be further investigated, and aside from TSPO
other targets such as type 2 cannabinoid receptors, the purinergic receptor P2X7, and matrix
metalloproteinases are investigated currently. The power of protein or receptor tracers mainly
lies in the selectivity of their target, that is they selectively reflect one aspect of ALS patho‐
genesis which increases with disease progression. Hence, in contrast to FDG PET which reflects
general glucose metabolism, these tracers have the potential to be used as ‘positive tracers’ for
disease severity and progression. They are also of high interest to gain insight in the patho‐
physiology of ALS. Probably, several tracers assessing other aspects of ALS pathology will be
developed and investigated as well.
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